Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

/PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical...

Related Keywords

Boston ,Massachusetts ,United States ,San Diego ,California ,Tufts Medical Center ,Dublin ,Ireland ,Americans ,American ,Fredric Gordon ,Derek Belz ,Khurram Jamil ,Clin Transpl ,Heather Guzzi ,Ryan Taylor ,Danielj Speciale ,Prashant Pandya ,United States Census Bureau ,Clinical Development Critical Care At Mallinckrodt ,University Of Wisconsin Hospital ,American College Of Gastroenterology ,National Organization For Rare Disorders ,Exchange Commission ,American Transplant Congress ,Mallinckrodt Hospital Products Inc ,Mallinckrodt Pharmaceuticals ,Green Room Communications ,Important Safety Information ,Boxed Warning ,American Association ,Liver Diseases ,American College ,Adnan Said ,Wisconsin Hospital ,Vice President ,Clinical Development ,Critical Care ,Terlipressin Improves Clinical Outcomes ,Hepatorenal Syndrome Type ,Systemic Inflammatory Response Syndrome ,Pooled Analysis ,Hepatorenal Syndrome ,Fatal Respiratory Failure ,Liver Transplant ,Fetal Toxicity ,Prescribing Information ,Specialty Brands ,Specialty Generics ,Investor Relations ,Annual Report ,Green Room ,Mallinckrodt Hospital Products ,Improves Clinical Outcomes ,Data Report ,Nationwide Inpatient Sample ,States Census Bureau ,Current Management ,Acute Kidney Injury ,Mallinckrodt Plc ,